Company Filing History:
Years Active: 2014-2016
Title: Innovations by Jun-Jen Liu in Drug Delivery Systems
Introduction
Jun-Jen Liu is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of drug delivery systems, holding 2 patents that showcase his innovative approaches. His work focuses on developing advanced materials that enhance the efficacy of therapeutic agents.
Latest Patents
One of Liu's latest patents is a thermosensitive injectable hydrogel for drug delivery. This invention involves a hydrogel composed of hyaluronic acid (HA) and a copolymer of polyethylene oxide (PEO) and polypropylene oxide (PPO). The hydrogel exhibits a gel formation temperature ranging from 30°C to 37°C, providing a potential drug delivery system that can significantly increase the therapeutic efficacy of drugs.
Another significant patent is a liposome composition designed for delivering therapeutic agents to the eyes. This invention allows for the delivery of a high payload of therapeutic agents to neovascularization sites in patients. The liposome composition includes a variety of vesicle-forming lipids and an agent-carrying component that forms a complex with the therapeutic agent. The liposome composition has a mean particle diameter of about 30 to 200 nm and can accumulate at the neovascularization sites of the eyes within 24 hours after intravenous administration.
Career Highlights
Jun-Jen Liu has worked with esteemed institutions such as Taipei Medical University and Taiwan Liposome Company, Ltd. His experience in these organizations has contributed to his expertise in the development of innovative drug delivery systems.
Collaborations
Liu has collaborated with notable colleagues, including Hua-Jing Jhan and Hsiu-O Ho. These collaborations have further enriched his research and development efforts in the field of drug delivery.
Conclusion
Jun-Jen Liu's contributions to drug delivery systems through his innovative patents highlight his role as a leading inventor in this field. His work continues to pave the way for advancements in therapeutic efficacy and patient care.